Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MabSpace Biosciences of Suzhou Closes $40 Million B Round

publication date: May 10, 2018

Suzhou's MabSpace Biosciences completed a $40 million B round to support its antibody programs. Based on its proprietary discovery platform, MabSpace has formed discovery partnerships with other biopharmas while it has developed its own innovative portfolio of drug candidates. One month ago, the company began a US Phase I trial of its lead molecule, a PD-L1 antibody for cancer. It expects to begin a similar China trial soon. The B Round was led by Sequoia Capital China and joined by Lilly Asia Ventures and King Star. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital